On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety

A new experimental menopause drug has shown promising results in reducing hot flashes, with the company reporting an 83% reduction in moderate-to-severe episodes in a mid-stage clinical trial.

Shares of Canadian biotechnology company AbCellera surged nearly 40% on Monday after it announced positive results for ABCL635, an experimental non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause.

The Phase 2 study involved 92 women. After four weeks, women who received a single 600-mg dose of ABCL635 experienced an 83% reduction in the frequency of moderate-to-severe hot flashes, equivalent to 8.8 fewer episodes per day from baseline. The placebo group reported a 33% reduction, or 3.5 fewer episodes per day.

The treatment also improved the severity of symptoms, sleep and women's overall assessment of their improvement, according to the company.

The most commonly reported side effects, however, included headache, fatigue and reactions at the injection site.

What Makes This Drug Significant?

ABCL635 takes a different approach from hormone replacement therapy (HRT). It is a non-hormonal antibody treatment that targets the neurokinin 3 receptor, or NK3R, a protein involved in the brain's regulation of body temperature.

During menopause, falling estrogen levels can disrupt the activity of a group of brain cells known as KNDy neurons. This can make the body's temperature-control system overly sensitive, triggering hot flashes. By blocking NK3R signaling, ABCL635 is designed to help restore that balance.

Also read: Lifestyle Genetics And Hormones: Understanding The Interplay Of Risk Factors For Ovarian Cancer

More About The Drug

One of the drug's potential advantages is its dosing. ABCL635 is being developed as a long-acting, once-monthly injection, rather than a daily pill.

AbCellera's chief medical officer Sarah Noonberg said the approach could appeal to women already accustomed to self-injecting medicines and could potentially improve adherence compared to daily dosing.

When the Phase 2 programme began, Noonberg said: “Menopausal symptoms can have a profound impact on quality of life,” adding that the company wanted to assess whether ABCL635 could offer women a safe and effective non-hormonal alternative.

However, the drug is still experimental and has not been approved for clinical use. AbCellera said additional 12-week trial data are expected later this year, which will provide a better picture of how long the benefits last and how the treatment performs over a longer period.

The drug development comes as non-hormonal menopause treatments are gaining popularity. FDA-approved options already include drugs targeting neurokinin pathways, including Astellas' Veozah and Bayer's Lynkuet, giving women alternatives when hormone therapy is unsuitable or not preferred.

Also read: Are Women More Likely To Experience More Severe Neurological Symptoms Of Long COVID Than Men? New Study Finds

Why Menopausal Hot Flashes Can Be Unnerving?

Hot flashes, also known as vasomotor symptoms, are among the most common symptoms of menopause. The Menopause Society says up to 80% of women experience hot flashes or night sweats at some point during the menopause.

A hot flash can begin suddenly, often as an intense wave of heat across the face, neck and chest. It may be followed by sweating, chills, dizziness, anxiety or racing heartbeat. When these episodes happen during sleep, they are known as night sweats.

Frequent hot flashes can repeatedly interrupt sleep, leaving women irritable and fatigued the next day. Poor sleep can then affect concentration, mood and daily functioning, creating a cycle in which one menopause symptom amplifies another.

US President Donald Trump has signed an executive order seeking major changes to the country’s childhood vaccination recommendations, including a proposal to split the measles, mumps and rubella (MMR) vaccine into three separate shots.

The order follows his long-standing view that some vaccines should be given separately over different medical visits.

The order, signed on August 10, calls for childhood vaccines to be administered at separate medical visits whenever possible and narrows the federal recommendations to vaccines against 11 core diseases.

It also directs federal health agencies to develop a plan for separate measles, mumps and rubella vaccines, which are currently not available as individual shots in the US.

Trump described the move as establishing “gold-standard” childhood vaccine recommendations and repeatedly raised the topic of vaccine and autism during the signing ceremony.

However, medical experts and lawmakers have opposed the move, saying that the proposed changes are not supported by new scientific evidence.

Why Does Trump Want To Split The MMR Vaccine?

The MMR vaccine currently protects children against three diseases with a combination shot. Under existing CDC guidance, children receive two doses, generally at 12 to 15 months and again at 4 to 6 years.

The CDC says two doses of measles-containing vaccine are about 97% effective at preventing measles.

He recently increased pressure on Health Secretary Robert F. Kennedy Jr. to identify the cause of autism, something Kennedy had pledged to do with new research unveiled last year.

At a Cabinet meeting last month, Trump asked, "How are you doing on the autism research?" Kennedy replied, "We will have an answer for you."

Dr. Andrew Racine, president of the American Academy of Pediatrics, said the announcement could create unnecessary uncertainty for families.

“Science about vaccines and their efficacy has not changed,” Racine said.

Also read: Alexandria Ocasio-Cortez Plans To Freeze Eggs As She Eyes 2028 US Presidential Run

The Problem With Three Separate Shots

One of the biggest hurdles in implementing tis proposal is that individual measles, mumps and rubella vaccines are not currently available in the US.

Dr. Elizabeth Mack, a pediatric critical care physician, questioned how such a system would work.

“We don't have a system that supports this,” she said, raising questions about additional appointments and insurance coverage.

Merck, which manufactures the MMR vaccine, also said there is no published scientific evidence showing a benefit from splitting the combination vaccine. More injections and additional appointments could instead increase the chances of delayed or missed vaccinations.

Also read: Dr. Erica Schwartz Confirmed As CDC’s First Permanent Director In Nearly A Year

How Will This Impact Children?

Doctors are particularly concerned about separating the vaccines and keeping them too far apart. When children need multiple visits to receive protection against different diseases, there can be longer periods during which they remain unprotected.

Public health experts warn this could become especially problematic during outbreaks of diseases that can be prevented by vaccines.

The order also seeks to encourage states to reconsider vaccination requirements for schoolchildren, although states retain authority over school vaccine schedules.

The latest order follows earlier efforts by the Trump administration to overhaul the federal childhood vaccine schedule. In January, Kennedy’s Health and Human Services Department attempted to remove several vaccines from routine childhood recommendations.

That move was challenged in court and blocked by a federal judge. The new executive order seeks to reinforce the administration’s approach while that legal battle continues.

Republican Senator Bill Cassidy, a physician and chairman of the Senate health committee, also criticised the latest move. “I’m a doctor. This executive order is wrong,” Cassidy said. “The President does not have the expertise to make these changes.”

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Eli Lilly’s orforglipron, marketed as Foundayo, for weight management and type 2 diabetes.

With the approval, the UK has become the first country in Europe to authorize Lilly’s once-daily GLP-1 tablet. It is also the second oral GLP-1 weight-loss medicine authorized in the UK after Novo Nordisk’s Wegovy.

“As with all GLP-1 receptor agonists, this is a prescription-only medication, and the MHRA will keep the safety and effectiveness of orforglipron under close review,” said Julian Beach, MHRA Executive Director of Healthcare Quality and Access.

Who Can Take Foundayo?

Orforglipron is a prescription-only pill and is authorised for weight loss and weight maintenance in adults with:

• A BMI of 30 or above; or
• A BMI between 27 and 30 with at least one weight-related condition.
• It is also authorised to improve blood sugar control in adults with inadequately controlled type 2 diabetes.

How Is Foundayo Taken?

Unlike injectable GLP-1 medicines such as Wegovy and Mounjaro, Foundayo is taken as a once-daily tablet. It can be taken at any time of day, with no restrictions on food or water.

Treatment starts at 0.8 mg and is gradually increased through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with at least one month at each dose level. Patients should follow the dosing instructions provided with the medicine.

Is Foundayo Available on the NHS?

Although Foundayo has been authorized for use in the UK, it is not currently available through the NHS. The NHS availability will depend on established processes, including assessment by the National Institute for Health and Care Excellence (NICE).

The MHRA urged people to buy the prescription only GLP-1 medicines from a registered pharmacy, with a prescription from a doctor. Buying GLP-1 medicines from unregulated sellers carries serious health risks.

What Is Foundayo and How Does It Work?

Orforglipron is Eli Lilly’s first oral GLP-1 medicine for weight management, marketed as Foundayo. It was approved by the US Food and Drug Administration (FDA) in April this year.

The medicine is a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a hormone involved in appetite and blood sugar regulation.

By activating GLP-1 receptors, orforglipron helps reduce hunger and food cravings and increases feelings of fullness. Along with diet and lifestyle changes, this can support weight loss.

In people with type 2 diabetes, it also helps lower blood glucose levels. Unlike some oral GLP-1 medicines, orforglipron does not require patients to take it on an empty stomach or avoid food and water around the time of dosing.

Is Foundayo Better Than Injectable Mounjaro or Wegovy?

A recent clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian showed that Foundayo may be help prevent rebound weight gain caused by GLP-1 weight-loss drugs such as Wegovy and Mounjaro.

The ATTAIN-MAINTAIN trial included people who had previously taken tirzepatide or semaglutide and whose weight loss had plateaued.

• Among those who switched from tirzepatide, patients maintained an average 74.7% of their previous weight reduction, compared with 49.2% in the placebo group.
• Among those who switched from semaglutide, patients maintained 79.3% of their previous weight reduction, compared with 37.6% in the placebo group.

Foundayo: Side Effects and Safety Concerns

Foundayo is not approved for use in children. Its safety information also includes a warning about the potential risk of thyroid tumours, including thyroid cancer.

Patients should seek medical advice if they develop symptoms such as:

• A lump or swelling in the neck
• Hoarseness
• Difficulty swallowing
• Shortness of breath

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Stomach pain
• Headache
• Abdominal bloating
• Fatigue.